CD226 can compete with the inhibitory receptors CD96 and T cell immunoreceptor with Ig and ITIM domain (TIGIT) expressed on T cells for binding to CD155 overexpressed in tumor cells to exert anti-tumor effect [71]. Here, PVR is linked to neoplasm.